Compare MIRA & OFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIRA | OFS |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 46.2M |
| IPO Year | 2023 | N/A |
| Metric | MIRA | OFS |
|---|---|---|
| Price | $0.99 | $3.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 109.1K | 52.9K |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 16.83% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $2.72 |
| 52 Week High | $2.45 | $9.31 |
| Indicator | MIRA | OFS |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 39.75 |
| Support Level | $0.99 | $2.72 |
| Resistance Level | $1.24 | $4.40 |
| Average True Range (ATR) | 0.04 | 0.18 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 53.74 | 11.49 |
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.